Last reviewed · How we verify
NCT03605602: TRUMPRWS
A Real World Study Based on NGS (TRUMPRWS)
trial testing No treatment is included in this protocol. in Non-Small Cell Carcinoma of Lung, TNM Stage 4 in 2,700 participants. Status unknown.
30 December 2022
Quick facts
| Lead sponsor | Guangdong Association of Clinical Trials |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 2,700 |
| Start date | 1 August 2018 |
| Primary completion | 30 December 2022 |
| Estimated completion | 30 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- No treatment is included in this protocol.
Conditions studied
- Non-Small Cell Carcinoma of Lung, TNM Stage 4 — all drugs for Non-Small Cell Carcinoma of Lung, TNM Stage 4 →
Sponsor
Guangdong Association of Clinical Trials
Who can join
18 and older, any sex, with Non-Small Cell Carcinoma of Lung, TNM Stage 4. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a descriptive observational study, in which data are collected in an epidemiological fashion. This study does not intend to alter or intervene the current medical practice of the recruited patients. Data will be collected in prospective manner.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Oncogenic alterations in advanced NSCLC: a molecular super-highway.
Friedlaender A, Perol M, Banna GL, Parikh K, et al · · 2024 · cited 91× · PMID 38347643 · DOI 10.1186/s40364-024-00566-0 -
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial.
Liu SM, Tu HY, Wei XW, Yan HH, et al · · 2023 · cited 44× · PMID 37488286 · DOI 10.1038/s41591-023-02461-x -
[Advances in Targeted Therapy for Advanced Non-small Cell Lung Cancer
with HER2 Mutation].
Yu J, Cao B. · · 2025 · PMID 41158042 · DOI 10.3779/j.issn.1009-3419.2025.106.22
Verify or expand the search:
- PubMed search for NCT03605602
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of No treatment is included in this protocol.
Trials testing the same drug.
- NCT06183762 — A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer · recruiting
Other recruiting trials for Non-Small Cell Carcinoma of Lung, TNM Stage 4
Currently open trials in the same condition.
- NCT03774732 — PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cance · Phase 3 · active not recruiting
- NCT03042221 — Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy · recruiting
Other Guangdong Association of Clinical Trials trials
Trials by the same sponsor.
- NCT07412262 — A Prospective, Single-Arm, Multicenter, Phase II Clinical Study of Chidamide Combined With Ivonescimab in the Treatment · Phase 2 · not yet recruiting
- NCT07416058 — PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC · Phase 2 · not yet recruiting
- NCT07375316 — A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC · Phase 2 · recruiting
- NCT07120698 — Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung) · Phase 2 · recruiting
- NCT07198620 — A Real-World Study of IBI351 for KRAS G12C+ NSCLC in China · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03605602 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangdong Association of Clinical Trials
- Last refreshed: 7 February 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03605602.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing